The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
From Multimodal biomedical AI (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [118]
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [27]
In the citing paper
“Cancer genome sequencing efforts yielded an unexpected discovery in 2008 with the identification of somatic mutations in a metabolic enzyme, the TCA cycle enzyme IDH1, in glioblastoma multiforme (GBM) (77).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [77]
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,713
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citation
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- H. Scherer, Am. J. Cancer40, 159 (1940).
- R. J. Learyet al. Proc. Natl. Acad. Sci. U.S.A. in press.
- K. Uekiet al., Cancer Res.56, 150 (1996).
- L. Frederick, X. Y. Wang, G. Eley, C. D. James, Cancer Res.60, 1383 (2000).
- G. Thielet al., Anticancer Res.15, 2495 (1995).
- S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Methods Mol. Biol.356, 319 (2007).
- Contact information for the authors who directed the major components of this project is as follows: H. Yan G. J. Riggins (clinical and sample coordination) yan00002@mc.duke.edu griggin1@jhmi.edu; D. D. Bigner (pathological and clinical review) bigne001@mc.duke. edu; R. Karchin (bioinformatic analysis) karchin@jhu.edu; N. Papadopoulos (gene expression analysis) npapado1@jhmi.edu; G. Parmigiani (statistical analysis) gp@jhu.edu; B. Vogelstein V. E. Velculescu K. W. Kinzler (sequencing and copy number analysis) bertvog@gmail.com velculescu@jhmi.edu kinzlke@jhmi.edu. We thank N. Silliman J. Ptak L. Dobbyn and M. Whalen for assistance with PCR amplification; D. Lister L. J. Ehinger D. L. Satterfield J. D. Funkhouser and P. Killela for assistance with DNA purification; T. Sjöblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research NIH grants CA121113 NS052507 CA43460 CA57345 CA62924 CA09547 5P50-NS-20023 CA108786 and CA11898 the Pew Charitable Trusts the Pediatric Brain Tumor Foundation Institute the Hirschhorn Foundation Alex's Lemonade Stand Foundation the American Brain Tumor Association the American Society of Clinical Oncology the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme Beckman Coulter and Exact Sciences Corporations B.V. V.E.V. and K.W.K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
Cited by
Sorted by citations
Items 601–700 of 1,034
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
Circulating biomarkers for gliomas
Westphal, M., & Lamszus, K. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.171 · Cited by 183
Mutational analysis of primary central nervous system lymphoma
Bruno, A., Boisselier, B., Labrèche, K., Marie, Y., Polivka, M., Jouvet, A., Adam, C., Figarella‐Branger, D., Miquel, C., Eimer, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2080 · Cited by 183
Models for prevention and treatment of cancer: Problems vs promises
Aggarwal, B. B., Danda, D., Gupta, S. R., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 184
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Tiong, K. H., Mah, L. Y., & Leong, C. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0886-7 · Cited by 181
PDGF and PDGF receptors in glioma
Nazarenko, I., Hede, S., He, X., Hedrén, A., Thompson, J., Lindström, M. S., & Nistér, M. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.665097 · Cited by 191
Blümcke, I., Aronica, E., Urbach, H., Alexopoulos, A. V., & Gonzalez-Martinez, J. A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1288-9 · Cited by 178
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhäuser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 182
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia
Radtke, I., Mullighan, C. G., Ishii, M., Su, X., Cheng, J., Ma, J., Ganti, R., Cai, Z., Goorha, S., Pounds, S. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903142106 · Cited by 178
de Souza, C. F., Sabedot, T. S., Malta, T. M., Stetson, L. C., Morozova, O., Sokolov, A., Laird, P. W., Wiznerowicz, M., Iavarone, A., Snyder, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.107 · Cited by 187
Glioblastoma cancer stem cell biology: Potential theranostic targets
Sharifzad, F., Ghavami, S., Verdi, J., Mardpour, S., Sisakht, M. M., Azizi, Z., Taghikhani, A., Łoś, M., Fakharian, E., Ebrahimi, M., et al. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.003 · Cited by 186
A novel approach for data integration and disease subtypingPreprint
Nguyen, T., Tagett, R., Diaz, D., & Drăghici, S. (2017) · Genome Research · doi:10.1101/gr.215129.116 · Cited by 183
Mutational spectra of human cancer
Pfeifer, G. P., & Nia, A. B. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 180
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation
Patel, K. P., Ravandi, F., Ma, D., Paladugu, A. V., Barkoh, B. A., Medeiros, L. J., & Luthra, R. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpd7nr2rmnqdvf · Cited by 179
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 184
Choi, D., Montermini, L., Kim, D., Meehan, B., Roth, F. P., & Rak, J. W. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000644 · Cited by 183
Epigenetic mechanisms in glioblastoma multiforme
Nagarajan, R. P., & Costello, J. F. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.02.005 · Cited by 176
Orr, B. A., Haffner, M. C., Nelson, W. G., Yegnasubramanian, S., & Eberhart, C. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041036 · Cited by 180
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 180
Komori, T. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00667-6 · Cited by 176
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylationPreprint
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 183
Self-citationSheng, Z., Li, L., Zhu, L. J., Smith, T. W., Demers, A., Ross, A. H., Moser, R. P., & Green, M. R. (2010) · Nature Medicine · doi:10.1038/nm.2158 · Cited by 175
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
von Deimling, A., Korshunov, A., & Hartmann, C. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00454.x · Cited by 178
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 184
Dual IRE1 RNase functions dictate glioblastoma development
Lhomond, S., Avril, T., Dejeans, N., Voutetakis, K., Doultsinos, D., McMahon, M., Pineau, R., Obacz, J., Papadodima, O., Jouan, F., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201707929 · Cited by 189
From human genome to cancer genome: The first decadePreprint
Wheeler, D. A., & Wang, L. (2013) · Genome Research · doi:10.1101/gr.157602.113 · Cited by 183
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 178
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Pusch, S., Krausert, S., Fischer, V., Balß, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1677-y · Cited by 179
Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. D. (2011) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 179
Identification of disease treatment mechanisms through the multiscale interactome
Ruiz, C., Zitnik, M., & Leskovec, J. (2021) · Nature Communications · doi:10.1038/s41467-021-21770-8 · Cited by 172
Metabolism unhinged: IDH mutations in cancer
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Nature Medicine · doi:10.1038/nm0311-291 · Cited by 175
Qi, S., Yu, L., LI, H., Ou, Y.-H., Qiu, X., Ding, Y., Han, H.-X., & ZHANG, X. (2014) · Oncology Letters · doi:10.3892/ol.2014.2013 · Cited by 172
Self-citationMiao, H., Gale, N. W., Guo, H., Qian, J., Petty, A. P., Kaspar, J., Murphy, A. J., Valenzuela, D. M., Yancopoulos, G. D., Hambardzumyan, D., et al. (2014) · Oncogene · doi:10.1038/onc.2013.590 · Cited by 182
Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Alfaro-Munoz, K. D., Mischel, P. S., Kelly, J. R., McGown, G., Thorncroft, M. R., Carlson, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59334 · Cited by 176
Wang, S., Hong, J., Hsueh, C., & Chiang, C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.128 · Cited by 172
Tumor Heterogeneity: Mechanisms and Bases for a Reliable Application of Molecular Marker Design
Díaz‐Cano, S. J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021951 · Cited by 179
Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI
Jiang, S., Zou, T., Eberhart, C. G., Villalobos, M. A. V., Heo, H., Zhang, Y., Wang, Y., Wang, X., Yu, H., Du, Y., et al. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26820 · Cited by 172
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Diplas, B. H., He, X., Brosnan‐Cashman, J. A., Liu, H., Chen, L. H., Wang, Z., Moure, C. J., Killela, P. J., Loriaux, D. B., Lipp, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04448-6 · Cited by 175
Self-citationConnections between metabolism and epigenetics in cancers
Thakur, C., & Chen, F. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.006 · Cited by 176
Metabolic analysis as a driver for discovery, diagnosis, and therapy
DeBerardinis, R. J., & Keshari, K. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.029 · Cited by 177
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Glutamate and its receptors in cancer
Stepulak, A., Rola, R., Polberg, K., & Ikonomidou, C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1182-6 · Cited by 171
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 180
The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs
Kuroda, K., Okumura, K., Isogai, H., & Isogai, E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00144 · Cited by 170
An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 171
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Hartmann, C. J., Hentschel, B., Tatagiba, M. S., Schramm, J., Schnell, O., Seidel, C., Stein, R. J., Reifenberger, G., Pietsch, T., von Deimling, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3194 · Cited by 170
Dupuy, A. J., Rogers, L. M., Kim, J., Nannapaneni, K., Starr, T. K., Liu, P., Largaespada, D. A., Scheetz, T. E., Jenkins, N. A., & Copeland, N. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1135 · Cited by 172
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 172
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
Sensitivity analysis methods in the biomedical sciences
Qian, G., & Mahdi, A. (2020) · Mathematical Biosciences · doi:10.1016/j.mbs.2020.108306 · Cited by 169
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 174
Self-citationDjuric, U., Zadeh, G. M., Aldape, K., & Diamandis, P. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0022-1 · Cited by 179
Radioresistance in Glioblastoma and the Development of Radiosensitizers
Ali, M. Y., Oliva, C. R., Noman, A. S. M., Allen, B. G., Goswami, P. C., Zakharia, Y., Monga, V., Spitz, D. R., Buatti, J. M., & Griguer, C. E. (2020) · Cancers · doi:10.3390/cancers12092511 · Cited by 183
The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism
Chinnaiyan, P., Kensicki, E., Bloom, G. C., Prabhu, A. H., Sarcar, B., Kahali, S., Eschrich, S. A., Qu, X., Forsyth, P. A., & Gillies, R. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1572-t · Cited by 172
The origins of cancer robustness and evolvability
Tian, T., Olson, S., Whitacre, J. M., & Harding, A. S. (2010) · Integrative Biology · doi:10.1039/c0ib00046a · Cited by 174
Clonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G. A., & Wu, C. J. (2013) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 173
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. R. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 175
Mutant proteins as cancer-specific biomarkers
Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J., Papadopoulos, N., Kopelovich, L., Maitra, A., Matthaei, H., Eshleman, J. R., Hruban, R. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019203108 · Cited by 170
Self-citationEmerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C., DeAngelis, L. M., & Omuro, A. M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 173
Syed, N., Langer, J., Janczar, K., Singh, P., Nigro, C. L., Lattanzio, L., Coley, H. M., Hatzimichael, E. C., Bomalaski, J. S., Szlosarek, P. W., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2012.197 · Cited by 167
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Arceci, R. J. (2009) · Yearbook of Oncology · doi:10.1016/s1040-1741(09)79352-2 · Cited by 167
A Review of Newly Diagnosed Glioblastoma
Oronsky, B. T., Reid, T. R., Oronsky, A. L., Sandhu, N., & Knox, S. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574012 · Cited by 177
Qiu, S., Lin, S., Hu, D., Feng, Y., Tan, Y., & Peng, Y. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-10 · Cited by 169
Schreck, K. C., Taylor, P. H., Marchionni, L., Gopalakrishnan, V., Bar, E. E., Gaiano, N., & Eberhart, C. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1624 · Cited by 169
Binder, Z. A., Thorne, A. H., Bakas, S., Wileyto, E. P., Bilello, M., Akbari, H., Rathore, S., Ha, S. M., Zhang, L., Ferguson, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.006 · Cited by 166
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 168
Babić, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.013 · Cited by 169
When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?
Chaichana, K. L., Cabrera‐Aldana, E. E., Jusué-Torres, I., Wijesekera, O., Olivi, A., Rahman, M., & Quiñones‐Hinojosa, A. (2014) · World Neurosurgery · doi:10.1016/j.wneu.2014.01.019 · Cited by 164
Self-citationCurrent understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Xie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002037 · Cited by 165
Targeting the DNA Damage Response in Cancer
Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 164
Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis
Spyk, S. L.-V., Thomas, N. S. T., Cooper, D. N., & Upadhyaya, M. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-623 · Cited by 163
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 170
Current practices and guidelines for clinical next-generation sequencing oncology testing
Strom, S. P., & Strom, S. P. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0004 · Cited by 163
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 169
Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 162
Self-citationSherer, C., & Snape, T. J. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.007 · Cited by 161
Zhang, P., Qin, X., Liu, L., Li, S., & Dong, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.562798 · Cited by 169
Myc-Driven glycolysis is a therapeutic target in glioblastoma
Tateishi, K., Iafrate, A. J., Ho, Q., Curry, W. T., Batchelor, T. T., Flaherty, K. T., Onozato, M. L., Lelic, N., Sundaram, S., Cahill, D. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2274 · Cited by 160
Surgical resection of malignant gliomas—role in optimizing patient outcome
Eyüpoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.279 · Cited by 166
Masica, D. L., & Karchin, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0180 · Cited by 162
Self-citationMetabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Kang, H., Fan, J., Lin, R., Elf, S., Ji, Q., Zhao, L., Jin, L., Seo, J. H., Shan, C., Arbiser, J. L., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.037 · Cited by 162
Mehta, S. V., Huillard, E., Kesari, S., Maire, C. L., Golebiowski, D., Harrington, E. P., Alberta, J. A., Kane, M., Theisen, M., Ligon, K. L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.035 · Cited by 165
Iacobuzio–Donahue, C. A. (2011) · Gut · doi:10.1136/gut.2010.236026 · Cited by 158
Lu, K. V., Zhu, S., Cvrljevic, A. N., Huang, T., Sarkaria, S. M., Ahkavan, D., Dang, J. H. T., Dinca, E. B., Plaisier, S. B., Oderberg, I. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0347 · Cited by 159
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 158
Self-citationA Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Bax, D. A., Mackay, A. G., Little, S. E., Carvalho, D. M., Viana‐Pereira, M., Tamber, N., Grigoriadis, A. E., Ashworth, A., Reis, R. M., Ellison, D. W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0438 · Cited by 160
Horbinski, C., Kofler, J., Kelly, L. M., MURDOCH, G. H., & Nikiforova, M. N. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c391be · Cited by 155
Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis
McGillicuddy, L. T., Longo, J. F., Hollstein, P. E., Kubek, S., Beroukhim, R., Raedt, T. D., Johnson, B. W., Williams, S. M. G., Nghiemphu, P. L., Liau, L. M., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.009 · Cited by 158
Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing
Huse, J. T., & Holland, E. C. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00234.x · Cited by 160
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Li, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 158
Kawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 154
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach‐Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 156
Andronesi, O. C., Loebel, F., Bogner, W., Marjańska, M., Heiden, M. G. V., Iafrate, A. J., Dietrich, J., Batchelor, T. T., Gerstner, E. R., Kaelin, W. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0656 · Cited by 153
Thompson, S. L., & Compton, D. A. (2010) · Chromosome Research · doi:10.1007/s10577-010-9179-y · Cited by 161
Gallo, L. H., Nelson, K. N., Meyer, A. N., & Donoghue, D. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.03.003 · Cited by 155
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Yan, H., Bigner, D. D., Velculescu, V. E., & Parsons, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2650 · Cited by 156
Self-citation
Metadata
- Authors
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K. N., Shinjo, S. M. O., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Corresponding author
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Angenendt, Philipp
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- ORCID
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Carter, Hannah
- Gallia, Gary L.
- Olivi, Alessandro
- McLendon, Roger
- Keir, Stephen
- Diaz, Luis A.
- Marie, Suely Kazue Nagahashi
- Yan, Hai
- Riggins, Gregory J.
- Bigner, Darell D.
- Karchin, Rachel
- Parmigiani, Giovanni
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- Venue
- Science
- Published
- 2008-09-26
- Volume
- 321
- Issue
- 5897
- Pages
- 1807-1812
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820389
- OpenAlex
- W2040827479
- Cited by
- 5,857
- References
- 51
- Citations by year
- 2026: 131 · 2025: 160 · 2024: 189 · 2023: 260 · 2022: 256 · 2021: 370 · 2020: 344 · 2019: 313 · 2018: 329 · 2017: 347 · 2016: 353 · 2015: 373 · 2014: 410 · 2013: 428 · 2012: 457
- FWCI
- 172.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- National Cancer Institute (CA108786., CA 57345, R01-CA121113, CA-121113, CA43460, CA-11898, R37CA043460, CA09547, P50CA108786, R01CA140316, P50CA062924, R37CA057345, T32CA009547, CA 62924)
- National Institute of Neurological Disorders and Stroke (5P50NS20023, R01NS052507, NS052507)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, IDH1 mutation, IDH1, somatic mutations, gene amplification, gene deletion, gene expression profiling, secondary glioblastoma, overall survival, targeted therapy
- MeSH terms
- Adult, Brain Neoplasms, Female, Gene Amplification, Glioblastoma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Rate, Sequence Analysis, DNA, Gene Dosage, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
